Syntaxin’s TSI are novel recombinant proteins designed to exploit the unique pharmacology inherent in bacterial toxins
View how it works >
Syntaxin focuses its programmes in therapeutic areas where there is a high unmet need.
View Patient Focus >
Syntaxin has an alliance with Allergan, Inc. a world leader in the commercialisation of botulinum neurotoxin products to discover, develop and commercialise TSI for the treatment of pain in humans.
03 January 2012
Syntaxin to Present at Biotech Showcase™ 2012
Oxford (UK), 3 January 2012 – Syntaxin, a biotechnology company specia...
20 October 2011
Syntaxin and Ipsen enter into a strategic agreement to develop novel botulinum-toxin therapeutics
Ipsen (Euronext: IPN, ADR: IPSEY) and Syntaxin, a biotechnology compan...
BioBusiness 31 January-2 February 2012. London, UK
SACHs 5th Annual European Life Science CEO Forum 6-7 March 2012. Zurich, Swizerland